Clinical trials: SGLT2 Inhibitor
SGLT-2 Inhibitors, Advanced Glycation End Products
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
Single-center open-label multiple dose randomized two period cross-over study to examine Advanced Glycation End Product (AGE) levels in human subjects pre and post empagliflozin administration.
- Conditions
- SGLT-2 Inhibitors, Advanced Glycation End Products, Diabetes
- Trial name
- NCT02768220
- Testing
- empagliflozin, linagliptin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin)…
- Trial name
- EMMED-HF (NCT04071626)
- Testing
- Ertugliflozin 5 mg
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University Hospitals Cleveland Medical Center
Type 1 Diabetes Mellitus
Dapagliflozin Plus Pioglitazone in T1DM
Purpose: To examine the effect of addition of combination therapy with dapagliflozin plus pioglitazone to insulin on glucose control and plasma ketone concentration in patients with type 1 diabetes (T1DM) Research Design: 120…
- Trial name
- NCT03878459
- Testing
- Pioglitazone 45 mg
- Where
- 3 sites in United States, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type2Diabetes
Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients
The aim of the study is to evaluate the benefits, documented in experimental settings, of treatment with SGLT2-i in subjects with type 2 diabetes and older than 70 years in normal clinical practice.
- Trial name
- SOLDMiDiab02 (NCT05477017)
- Testing
- SGLT2 inhibitor
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- University of Milan
Obesity, Non-diabetic Chronic Kidney Disease
SGLT2 Inhibitors in Glomerular Hyperfiltration
Glomerular hyperfiltration is a major risk factor for accelerated glomerular filtration rate (GFR) decline and renal and cardiovascular events despite optimized conservative therapy with blood pressure and blood glucose (in…
- Trial name
- EMPATHY (NCT04143581)
- Testing
- Empagliflozin 10 MG
- Sponsor
- Mario Negri Institute for Pharmacological Research
Heart Failure, Coronary Arterial Disease
Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting
This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection…
- Trial name
- DAPA-RV-CABG (NCT07601867)
- Where
- Russia
- Volunteers
- 72 people
- Sponsor
- Pyatigorsk City Clinical Hospital Number 1
Cystinuria
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
Cystinuria is an inherited autosomal recessive disorder of the kidney that is the result of an inability to reabsorb cystine from the urine.
- Trial name
- NCT04818034
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Type2 Diabetes
Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin
The change of glycemic variation and insulin dose after adding SGLT2 inhibitor in type 2 diabetic patients treated with basal insulin was observed in a single center.
- Trial name
- NCT03631134
- Testing
- SGLT2 inhibitor
- Volunteers
- 100 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
CAD - Coronary Artery Disease, Inflamation
Effect of Empagliflozin on Inflammation
Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure.
- Conditions
- CAD - Coronary Artery Disease, Inflamation, PCI, SGLT 2 Inhibitors
- Trial name
- EMPANTINFLAM (NCT07292909)
- Testing
- Empagliflozin (SGLT2i)
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Hotel Dieu de France Hospital
Type 1 Diabetes Mellitus
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
The objective of this study is to confirm efficacy of ASP1941 based on the changes in HbA1c and to assess its safety in subjects with type 1 diabetes mellitus receiving ASP1941 once daily in combination with insulin for 24 weeks.
- Trial name
- NCT02897219
- Testing
- ipragliflozin, Insulin Therapy
- Where
- 36 sites in Japan
- Volunteers
- 175 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
The aim of this project is to identify subgroups of patients with type 2 diabetes that respond well or poorly to particular drugs based on particular clinical characteristics such as their weight or kidney function, to enable…
- Trial name
- TriMaster (NCT02653209)
- Testing
- Sitagliptin - DPP4i, Canagliflozin - SGLT2i, Pioglitazone - TZD
- Where
- United Kingdom
- Volunteers
- 525 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors
Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes.
- Trial name
- NCT02528019
- Testing
- DPP-4 inhibiotors, SGLT2 inhibitors, Glimepiride
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kurume University
Diabetic Ketoacidosis, Postoperative Care
Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users
The goal of this observational study is to determine the frequency of postoperative euglycemic diabetic ketoacidosis (EDKA) in patients receiving Sodium- Glucose Cotransporter-2 (SGLT-2) inhibitors.
- Trial name
- SGLT-2I (NCT07127406)
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kocaeli City Hospital
Cardiovascular Diseases
Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
Purpose: The overall hypothesis of the study is that the benefits attained in the EMPA-OUTCOME were, at least in part, mediated by a glucose-independent mechanism.
- Trial name
- EMPA-TROPISM (NCT03485222)
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Acute Heart Failure (AHF)
Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department
Background: SGLT2 inhibitors reduce CHF morbidity/mortality but are underutilized in elderly patients with acute decompensated CHF (ADCHF) admitted outside cardiology departments.
- Trial name
- GlifloFastER (NCT07392788)
- Testing
- Early initiation of dapagliflozin 10mg daily within 24h of emergency department admission, Telephone follow-up by cardiac nurse practitioner at 1 month, Standard acute decompensated heart failure care
- Volunteers
- 144 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Obesity, Pre-diabetes
SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue.
- Trial name
- NCT04907214
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt University Medical Center
Chronic Heart Failure With Reduced Systolic Function
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart…
- Trial name
- DEFINE-HF (NCT02653482)
- Testing
- Dapagliflozin
- Where
- 25 sites in United States
- Volunteers
- 263 people
- Sponsor
- Saint Luke's Health System
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where fat builds up in the liver, is common in patients with type 2 diabetes.
- Trial name
- NCT07269197
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Where
- Croatia
- Volunteers
- 67 people
- Sponsor
- Josip Juraj Strossmayer University of Osijek
Diabete Type 2
Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
Our trial goal is to determine the efficacy and safety of sitagliptin in comparison with empagliflozin in type 2 diabetic Egyptian patients.
- Trial name
- NCT05359341
- Testing
- Sitagliptin 50 mg, Empagliflozin 12.5 MG, Sitagliptin 50 mg + Empagliflozin 12.5 MG
- Where
- Egypt
- Volunteers
- 175 people
- Sponsor
- Sadat City University
Type 2 Diabetes
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
- Trial name
- START (NCT05345327)
- Testing
- Dapagliflozin, Metformin
- Where
- 8 sites in Australia, Sri Lanka
- Volunteers
- 994 people
- Sponsor
- The George Institute